Published by Persistence MarketResearch
Posted on September 23, 2021
6 min readLast updated: February 2, 2026
The saliva-based screening market is set to grow at an 8% CAGR, reaching $277 Mn by 2031, driven by technological advancements in diagnostic testing.
The Saliva-based Screening Market will witness a CAGR of 8% by reaching US$ 277 Mn from 2021-2031. The new-fangled healthcare electronic technologies like 3D printing, GPS tracking, and wearable biometric devices are being tested concerning clinical use. Cutting-edge technology is expected to be one of the driving forces in the healthcare industry in the subsequent decade.
As per Persistence Market Research’s latest industry analysis, the global saliva-based screening market was valued at US$ 277 Mn in 2020, and is expected to exhibit a CAGR of 8% over the forecast period 2021-2031.
Rapidly developing technology in point-of-care testing is driving demand for saliva-based screening. There has been prompt growth in the adoption of saliva as a diagnostic specimen in the last few decades. There have been major advances including application of saliva as a clinically relevant specimen. The advent of new and more sensitive technologies to detect minimum analyte concentrations in saliva and upward research in saliva-based genomics and proteomics has been witnessed over the years.
Availability of improved saliva collection devices is one such example: RNAPro.SAL – Split Sample Kit for Liquid Biopsy, Pure.SAL (Oasis Diagnostics), Salivabio Oral Swab (SOS) (Salimetrics), and SDNA Saliva Collection Devices – IVD Molecular Diagnostic Testing (Spectrum Solutions LLC). Thus, availability of a safe, simple, and non-invasive method for the collection of samples provides lucrative growth opportunities for market players.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32714
Although serum-based testing remains the gold standard for detecting HIV infections, in recent years, saliva-based HIV screening has been extensively used to diagnose diseases. The oral mucosal transudate (OMT), which is found by swabbing the tongue and buccal mucosa, contains a mixture of antibodies of immunoglobulin isotypes IgG, IgA, and IgM. Thus, easy availability of HIV antibodies in human saliva and reduced risk of infection make saliva-based screening a preferred choice for HIV testing.
Additionally, real-time results, shorter turnaround time, availability of in-home HIV tests diagnostic testing, and ease of sample collection for larger population base specifically in developing economies are expected to boost adoption of saliva-based testing for HIV diagnosis.
Key market players are focusing on the expansion of their product portfolios through acquisitions and collaborations.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32714
Company Profiles:
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32714
Key Takeaways from Market Study
“Growing adoption of saliva-based screening, increasing demand for self-testing/home-based saliva based screening, and growing technological advancements are estimated to boost market growth over the coming years,” says an analyst of Persistence Market Research.
Market Competition
Mergers, acquisitions, and expansion of manufacturing facilities around the globe are expected to introduce new opportunities into the market. Introducing new products with improved sensitivity and specificity will able leveraging of untapped market opportunities. Moreover, manufacturers are involved in research & development activities for the application of saliva-based screening in various research applications.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the saliva-based screening market in its latest study, presenting a historical demand assessment and projections for 2016 – 2031.
The research study is based on the product (saliva collection kits, saliva nucleic acid purification kit and saliva based detection kits), purpose (research use only and diagnostics), application (infection analysis/detection (non-COVID), genomic analysis, proteomics, pharmacogenomics and liquid biopsy), end-user (hospitals & clinics, diagnostic laboratories, academic and research institutes, biopharmaceuticals and CROs), across seven key regions of the world.
Related Reports:
Generic Oncology Drugs Market:
Generic Oncology Drugs has grown into an effective treatment option for indicative cancer cases, the manufacturers on the other end are focusing on introducing new product with quality difference over present product.
Endoscopic Submucosal Dissection Market:
The global endoscopic submucosal dissection market was valued at US$ 200 Mn in 2018, and is expected to exhibit a healthy CAGR of 7.5% over the estimation period (2019–2029).
Endoscopic Spinal Surgery Market:
The global endoscopic spinal surgery market was valued at US$ 573.6 Mn in 2020, and is expected to exhibit a CAGR of over 8% through the forecast period (2021 – 2031).
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
The post Saliva-based Screening Market To Check Through Innovation (Reaching US$ 277 Mn) In The Next 10 Years appeared first on Lake Shore Gazette.
The article discusses the growth and innovation in the saliva-based screening market, projected to reach $277 Mn by 2031.
Technological advancements in point-of-care testing and increased adoption of saliva as a diagnostic specimen drive growth.
Saliva-based detection kits and diagnostics are key segments, with hospitals and clinics as primary end users.
Explore more articles in the Research Reports category
